Melanoma clinical trials
Showing 151–200 of 257 active trials. Describe your situation to see which ones you may be eligible for.
- Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type
- A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
- In Vivo Liquid Biopsy of Melanoma (Cytophone)
- DermaSensor Postmarket Surveillance Study
- MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors
- Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
- Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma
- Evaluation of Hypoxia in Primary Melanoma
- Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant App
- Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi
- Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
- Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
- Quality of Life, Lifestyle, and Psychosocial Factors in Patients With Melanoma
- Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
- A Storage Facility for Tissues Obtained From Patients With Malignant Melanoma
- Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
- Observational Study of Iris Tumors
- In Vivo Real-time Detection of Circulating Melanoma Cells
- Storage and Research Use of Human Bio-specimens From Melanoma Patients and Clinical Testing for Assignment of Treatment
- Symptom Management and Survivorship Plus Coaching for Advanced Cancer Survivors and Their Caregivers
- Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
- A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
- Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
- Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Intratumoral N17350 in Advanced Solid Tumors
- Navigation Intervention for Adolescent and Young Adult Cancer Survivors
- Evaluation for NCI Surgery Branch Clinical Research Protocols
- Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
- Sample Collection for Ongoing Research and Product Evaluation Study
- DESTINY-PANTUMOUR04
- End Diagnostic Overshadowing:Addressing Ableism in Diagnoses
- Pan-tumor MRD Study
- Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
- BostonGene and Exigent Genomic INsight Study
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
- Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
- Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
- Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
- Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
- Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
- Cancer Experience Registry (CER) for Cancer Patients and Caregivers
- Integrated Cancer Repository for Cancer Research
- Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
- Investigating Real-Time Immunotherapy Symptoms Study
- The Multicentre Selective Lymphadenectomy Trial - 3
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.